Cue biopharma reports third quarter 2020 results and cue-101 phase 1 dose escalation trial updates

Cambridge, mass., nov. 17, 2020 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted t cells within the patient's body, provided a business update for the third quarter of 2020.
CUE Ratings Summary
CUE Quant Ranking